ArticleClinical pharmacology and therapeutics2018
Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy.
Open access · bronzeAbstract readComparative StudyMulticenter Study
In one paragraph
Article in Clinical pharmacology and therapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.
0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed
9.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 127 citations in OpenAlex.
- The Impact of CYP2C19 Genotype on the Platelet Reactivity Index (PRI) among Chronic Coronary Syndromes (CCS) Patients Undergoing Percutaneous Coronary Intervention (PCI): Affectability of Rapid Genetic Testing.Cardiovascular drugs and therapy · 2025Trial
- Lessons learned from two clinical trials on nutritional supplements to reduce aggressive behaviour.Journal of evaluation in clinical practice · 2022Trial
- Efficacy of personal pharmacogenomic testing as an educational tool in the pharmacy curriculum: A nonblinded, randomized controlled trial.Clinical and translational science · 2021Trial
- Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention.Journal of translational medicine · 2018Trial
- CYP2C19 Genotyping to Guide Clopidogrel Prescribing for Neurovascular Indications: A Survey of Institutional Approaches.Clinical pharmacology and therapeutics · 2026Article
- The role of pharmacogenomics in epilepsy treatment: advancements in personalized medicine.The pharmacogenomics journal · 2026Review
- Pharmacogenetics-Guided De-Escalation of Dual Antiplatelet Therapy Based on CYP2C19 Testing in Patients After Acute Coronary Syndrome: Clinical Outcomes and Cost-Consequence Analysis.Journal of clinical medicine · 2026Article
- Global Investigation of Clinical Implementation Strategies for DPYD Testing to Guide Fluoropyrimidine Therapy.Clinical and translational science · 2026Article
- Progress in Pharmacogenomics Implementation in the United States: Barrier Erosion and Remaining Challenges.Clinical pharmacology and therapeutics · 2025Review
- Article
- The Pharmacogenomics Global Research Network Implementation Working Group: global collaboration to advance pharmacogenetic implementation.Pharmacogenetics and genomics · 2025Article
- CYP2C19 Genotype-Guided Antiplatelet Therapy and Clinical Outcomes in Patients Undergoing a Neurointerventional Procedure.Clinical and translational science · 2025Review
- Pharmacogenetics: Opportunities for theAnnual review of pharmacology and toxicology · 2025Review
- Development of a Multifaceted Program for Pharmacogenetics Adoption at an Academic Medical Center: Practical Considerations and Lessons Learned.Clinical pharmacology and therapeutics · 2024Article
- Genetic Determinants of Response to P2YInterventional cardiology clinics · 2024Review
- Genotype-Guided Antiplatelet Therapy: JACC Review Topic of the Week.Journal of the American College of Cardiology · 2024Review
- Precision Antiplatelet Therapy after Percutaneous Coronary Intervention (Precision PCI) Registry - Informing optimal antiplatelet strategies.Clinical and translational science · 2024Article
- Strategies for DPYD testing prior to fluoropyrimidine chemotherapy in the US.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Implementation of clopidogrel pharmacogenetic clinical decision support for a preemptive return of results program.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2024Article
- Decoding Pharmacogenomic Test Interpretation and Application to Patient Care.Journal of the American College of Clinical Pharmacy : JACCP · 2024Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 13 institutions in 1 country.
Philip E EmpeyDepartment of Pharmacy and Therapeutics, Center for Clinical Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania, USA.
James M StevensonDepartment of Pharmacy and Therapeutics, Center for Clinical Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania, USA.
Sony TutejaDepartment of Medicine, Division of Translational Medicine and Human Genetics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Kristin W WeitzelDepartment of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, University of Florida, Gainesville, Florida, USA.
Dominick J AngiolilloDepartment of Medicine, Division of Cardiology, University of Florida College of Medicine, Jacksonville, Florida, USA.
Amber L BeitelsheesDepartment of Medicine and Program for Personalized and Genomic Medicine, University of Maryland, Baltimore, Maryland, USA.
James C CoonsDepartment of Pharmacy and Therapeutics, Center for Clinical Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania, USA.
Julio D DuarteDepartment of Pharmacy Practice, University of Illinois at Chicago, Chicago, Illinois, USA.
Francesco FranchiDepartment of Medicine, Division of Cardiology, University of Florida College of Medicine, Jacksonville, Florida, USA.
Linda J B JengDepartment of Medicine and Program for Personalized and Genomic Medicine, University of Maryland, Baltimore, Maryland, USA.
Julie A JohnsonDepartment of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, University of Florida, Gainesville, Florida, USA.
Rolf P KreutzDepartment of Medicine, Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Nita A LimdiDepartment of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Kristin A MaloneyDepartment of Medicine and Program for Personalized and Genomic Medicine, University of Maryland, Baltimore, Maryland, USA.
Aniwaa Owusu ObengThe Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai; and Pharmacy Department, The Mount Sinai Hospital, New York, New York, USA.
Josh F PetersonDepartments of Biomedical Informatics and Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Natasha PetryDepartment of Pharmacy Practice, North Dakota State University, Fargo, North Dakota, USA.
Victoria M PrattDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Fabiana RolliniDepartment of Medicine, Division of Cardiology, University of Florida College of Medicine, Jacksonville, Florida, USA.
Stuart A ScottDepartment of Genetics and Genomics Sciences, Icahn School of Medicine at Mount Sinai, New York, NY and Sema4, a Mount Sinai venture, Stamford, Connecticut, USA.ORCID 0000-0001-5720-1864
Todd C SkaarDepartment of Medicine, Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Mark R VeselyDepartment of Medicine and Program for Personalized and Genomic Medicine, University of Maryland, Baltimore, Maryland, USA.
George A StoufferDivision of Cardiology, School of Medicine and McAllister Heart Institute, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Russell A WilkeDepartment of Internal Medicine, University of South Dakota Sanford School of Medicine, Sioux Falls, South Dakota, USA.
Larisa H CavallariDepartment of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, University of Florida, Gainesville, Florida, USA.
Craig R LeeDivision of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
IGNITE Network
University of Florida · USUniversity of Maryland, Baltimore · USIndiana University School of MedicineUniversity of Pittsburgh · USUniversity of North Carolina at Chapel Hill · USMount Sinai Hospital · USNorth Dakota State University · USSema4 (United States) · USUniversity of Alabama at Birmingham · USUniversity of Illinois Chicago · USUniversity of Pennsylvania · USUniversity of South Dakota · USVanderbilt University Medical Center · US
Funding
Vanderbilt Institute for Clinical and Translational Research (VICTR) -Identifying correlates of functional immunity in SARS-CoV-2 convalescent plasmaUL1TR002243 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Paul A. Harris, Wesley H Self · 2017 to 2026
$130.7MUniversity of Pittsburgh Clinical and Translational Science InstituteUL1TR000005 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2012 to 2015
$50.8MThe Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4MUsing social networks to map and evaluate team science across CTSA hubsUL1TR001427 · NCATS · UNIVERSITY OF FLORIDA · PI MITCHELL, DUANE A. · 2015 to 2024
$37.2MUAB Center for Clinical and Translational Science (CCTS)UL1TR001417 · NCATS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KIMBERLY, ROBERT P. · 2015 to 2018
$31.4MPharmacogenomic Evaluation of Antihypertensive ResponsesU01GM074492 · NIGMS · UNIVERSITY OF FLORIDA · PI JOHNSON, JULIE A. · 2005 to 2014
$20.7MSparking Advancements in Genomic MedicineU01HG007269 · NHGRI · UNIVERSITY OF FLORIDA · PI CAVALLARI, LARISA HUMMA, JOHNSON, JULIE A. · 2013 to 2024
$17.0MPharmacogenomics of Anti-platlet Intervention-2 (PAPI-2) StudyU01HL105198 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI SHULDINER, ALAN R. · 2010 to 2014
$13.6MUF Clinical and Translational Science AwardUL1TR000064 · NCATS · UNIVERSITY OF FLORIDA · PI NELSON, DAVID R · 2012 to 2014
$12.2MPredictors of hemorrhage among patients on direct acting oral anticoagulantsR01HL092173 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LIMDI, NITA A · 2008 to 2023
$10.4MUAB Center for Clinical and Translational Science (CCTS) UL1UL1TR000165 · NCATS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KIMBERLY, ROBERT P. · 2012 to 2013
$9.6MThe Electronic Medical Records and Genomics (eMERGE) Network Phase III Coordinating Center (U01)U01HG008701 · NHGRI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PETERSON, JOSEPH F. · 2015 to 2019
$7.1MAmerican Heart Association-American Stroke Association 17MCPRP33400176NCATS NIH HHS UL1 TR000005NCATS NIH HHS UL1 TR000064NCATS NIH HHS UL1 TR000165NCATS NIH HHS UL1 TR000445NCATS NIH HHS UL1 TR001417NCATS NIH HHS UL1 TR001427NCATS NIH HHS UL1 TR002243NHGRI NIH HHS U01 HG007253NHGRI NIH HHS U01 HG007269NHGRI NIH HHS U01 HG007278NHGRI NIH HHS U01 HG007762NHGRI NIH HHS U01 HG008701NHLBI NIH HHS K24 HL133373NHLBI NIH HHS R01 HL092173NHLBI NIH HHS U01 HL105198NHLBI NIH HHS U01 HL122904NIGMS NIH HHS K23 GM112014NIGMS NIH HHS U01 GM074492
Abstract
CYP2C19 genotype-guided antiplatelet therapy following percutaneous coronary intervention is increasingly implemented in clinical practice. However, challenges such as selecting a testing platform, communicating test results, building clinical decision support processes, providing patient and provider education, and integrating methods to support the translation of emerging evidence to clinical practice are barriers to broad adoption. In this report, we compare and contrast implementation strategies of 12 early adopters, describing solutions to common problems and initial performance metrics for each program. Key differences between programs included the test result turnaround time and timing of therapy changes, which are both related to the CYP2C19 testing model and platform used. Sites reported the need for new informatics infrastructure, expert clinicians such as pharmacists to interpret results, physician champions, and ongoing education. Consensus lessons learned are presented to provide a path forward for those seeking to implement similar clinical pharmacogenomics programs within their institutions.
Indexed as
Percutaneous Coronary InterventionPharmacogenomic TestingPharmacogenomic VariantsClinical Decision-MakingClopidogrelCytochrome P-450 CYP2C19GenotypeHumansInterdisciplinary CommunicationPatient Care TeamPatient SelectionPharmacogeneticsPhenotypePlatelet Aggregation InhibitorsPrecision MedicinePredictive Value of TestsClopidogrelCYP2C19 protein, humanCytochrome P-450 CYP2C19Platelet Aggregation Inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.